Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Sanofi-Aventis and BMS back NICE on vascular disease review

Sanofi-Aventis and BMS back NICE on vascular disease review

15th August 2008

Sanofi-Aventis and Bristol-Myers Squibb (BMS) have expressed their support for a decision by the National Institute of Clinical Health and Excellence (NICE) to review its guidance on vascular disease.

NICE is planning to review its guidance on Plavix (clipidogrel) and dipyridamole as treatments for vascular disease.

The companies said new evidence could result in a change in the guidance given by the institute.

NICE originally planned to defer review of the Technology Appraisal Number 90 (TAG90) until November 2010.

However, following consultation with a number of groups, NICE has opted to conduct an earlier review on this issue.

Nigel Brooksby, chairman and managing director of Sanofi-Aventis, said: “Cardiovascular diseases is Britain’s number one killer, therefore it is of public interest that NICE initiates a review of this guidance.”

He added new evidence in the area of stroke require a re-assessment in the guidance to keep it up to date.

Richard Marsh, director of external affairs and market access of BMS said the review of TAG90 is a timely one as it will replace the current guidelines which look at patients in isolation.

Last month, NICE published Social Value Judgements: Principles for the Development of NICE Guidance.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.